▶ FOLLISTATIN-344 · SUBTOPIC · SAFETY PROFILE
FOLLISTATIN-344 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of FOLLISTATIN-344.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of FOLLISTATIN-344. Severity, frequency, and attribution depend on the source publication.
- Injection-site reactions
- Theoretical risk of off-target activin pathway inhibition (HPG-axis effects)
- Limited published Western safety data
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for FOLLISTATIN-344.
- Concurrent activin-blocking therapy (theoretical additive effects)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for FOLLISTATIN-344 in the published record:
- Active malignancy
- Pregnancy/lactation
- Off-label muscle-wasting indications without clinical supervision
FDA REGULATORY STATUS
Not FDA-approved. Investigational compound. Research-use only.
WADA REGULATORY STATUS
Prohibited at all times under WADA Section S2 (Growth Factors and Myostatin Antagonists sub-category).
SAFETY Q+A FROM LITERATURE
▶ Is follistatin-344 FDA-approved?
No. Investigational compound. Research-use only.
▶ Is follistatin-344 WADA-prohibited?
Yes. Follistatin-344 is prohibited at all times under WADA Section S2 in the Growth Factors and Myostatin Antagonists sub-category.
▶ What are the side effects?
Limited published human safety data. Theoretical risks include off-target activin pathway inhibition (HPG-axis disruption from activin antagonism), and injection-site reactions. Animal-model evidence indicates greater safety than direct anti-myostatin antibodies, which have produced cardiac and HPG side effects in clinical trials.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Lee SJ, Lee YS, Zimmers TA, et al.. Regulation of muscle mass by follistatin and activins. Mol Endocrinol 2010. PMID 20801891. link
- Kota J, Handy CR, Haidet AM, et al.. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009. PMID 20371475. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25